Skip Navigation

Lotus provides a business update for the SEA markets

22 June 2020
  • Eight product approvals granted in 2020 with further 26 product submissions pending for approval across the fast-growing SEA region

Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today provided a business update for its commercial operation in South East Asia (SEA). After a very solid first quarter performance for the region, the Company has obtained a total of eight marketing approvals in the first six months of 2020. Lotus has also made another 26 product submissions pending for approval to further diversify and strengthen its product offering across the region.

Petar Vazharov, Chief Executive Officer of Lotus, commented:

We are so excited about being one of the pioneers in Taiwan by extending our leading oncology portfolio to serve patients and partners across the SEA region. By leveraging our strong networks with local partners, we are able to commercialize our pipeline ahead of the competition in a lean and efficient manner. I am proud of the whole team who have helped develop Lotus into having one of the strongest product portfolio’s for the SEA market, among all the Taiwanese players. We are confident that we will be continue delivering growth despite the challenges during COVID-19.

Petar Vazharov

Chief Executive Officer of Lotus

Market backdrop Lotus has announced that they have successfully integrated their operations in South East Asia and obtained eight marketing approvals YTD’20. This is in addition to the assets Lotus has acquired which further captures the fastest growing market in the world. The Company has started to consolidate revenues from the SEA market, which includes Thailand, Vietnam, Singapore, Philippines, Malaysia, Indonesia, Myanmar, Sri Lanka, and Bangladesh, since this quarter 2020.